376 related articles for article (PubMed ID: 14726483)
61. Synthetic oligonucleotides recruit ILF2/3 to RNA transcripts to modulate splicing.
Rigo F; Hua Y; Chun SJ; Prakash TP; Krainer AR; Bennett CF
Nat Chem Biol; 2012 Apr; 8(6):555-61. PubMed ID: 22504300
[TBL] [Abstract][Full Text] [Related]
62. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ
Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282
[TBL] [Abstract][Full Text] [Related]
63. Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity.
Crinelli R; Bianchi M; Gentilini L; Palma L; Sørensen MD; Bryld T; Babu RB; Arar K; Wengel J; Magnani M
Nucleic Acids Res; 2004; 32(6):1874-85. PubMed ID: 15051810
[TBL] [Abstract][Full Text] [Related]
64. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs.
Sazani P; Kang SH; Maier MA; Wei C; Dillman J; Summerton J; Manoharan M; Kole R
Nucleic Acids Res; 2001 Oct; 29(19):3965-74. PubMed ID: 11574678
[TBL] [Abstract][Full Text] [Related]
65. Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.
Shiraishi T; Eysturskarth J; Nielsen PE
BMC Cancer; 2010 Jun; 10():342. PubMed ID: 20591158
[TBL] [Abstract][Full Text] [Related]
66. Antisense Oligonucleotide-Based Splice Correction of a Deep-Intronic Mutation in CHM Underlying Choroideremia.
Garanto A; van der Velde-Visser SD; Cremers FPM; Collin RWJ
Adv Exp Med Biol; 2018; 1074():83-89. PubMed ID: 29721931
[TBL] [Abstract][Full Text] [Related]
67. Potential therapeutic applications of antisense morpholino oligonucleotides in modulation of splicing in primary immunodeficiency diseases.
Du L; Gatti RA
J Immunol Methods; 2011 Feb; 365(1-2):1-7. PubMed ID: 21147113
[TBL] [Abstract][Full Text] [Related]
68. Modification of alternative splicing of Bcl-x pre-mRNA in bladder cancer cells.
Zhu Z; Xing S; Cheng P; Zeng F; Lu G
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(2):213-6. PubMed ID: 16850750
[TBL] [Abstract][Full Text] [Related]
69. Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing.
Karras JG; McKay RA; Dean NM; Monia BP
Mol Pharmacol; 2000 Aug; 58(2):380-7. PubMed ID: 10908306
[TBL] [Abstract][Full Text] [Related]
70. Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells.
Benimetskaya L; Guzzo-Pernell N; Liu ST; Lai JC; Miller P; Stein CA
Bioconjug Chem; 2002; 13(2):177-87. PubMed ID: 11906253
[TBL] [Abstract][Full Text] [Related]
71. Antisense targeting of decoy exons can reduce intron retention and increase protein expression in human erythroblasts.
Parra M; Zhang W; Vu J; DeWitt M; Conboy JG
RNA; 2020 Aug; 26(8):996-1005. PubMed ID: 32312846
[TBL] [Abstract][Full Text] [Related]
72. Antisense experiments demonstrate an exon 4 minus splice variant mRNA as the basis for expression of tNOX, a cancer-specific cell surface protein.
Tang X; Morré DJ; Morré DM
Oncol Res; 2007; 16(12):557-67. PubMed ID: 18351130
[TBL] [Abstract][Full Text] [Related]
73. Improved nuclear delivery of antisense 2'-Ome RNA by conjugation with the histidine-rich peptide H5WYG.
Asseline U; Gonçalves C; Pichon C; Midoux P
J Gene Med; 2014; 16(7-8):157-65. PubMed ID: 25044540
[TBL] [Abstract][Full Text] [Related]
74. Optimization of 2',4'-BNA/LNA-Based Oligonucleotides for Splicing Modulation In Vitro.
Shimo T; Obika S
Methods Mol Biol; 2018; 1828():395-411. PubMed ID: 30171556
[TBL] [Abstract][Full Text] [Related]
75. Multiple competing RNA structures dynamically control alternative splicing in the human ATE1 gene.
Kalinina M; Skvortsov D; Kalmykova S; Ivanov T; Dontsova O; Pervouchine DD
Nucleic Acids Res; 2021 Jan; 49(1):479-490. PubMed ID: 33330934
[TBL] [Abstract][Full Text] [Related]
76. Antisense 2'-O-methyloligoribonucleotides hybridized to RNA block a nuclear, ATP-dependent 3'-5' exonuclease.
Dominski Z; Ferree P; Kole R
Antisense Nucleic Acid Drug Dev; 1996; 6(1):37-45. PubMed ID: 8783794
[TBL] [Abstract][Full Text] [Related]
77. Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design.
Braasch DA; Liu Y; Corey DR
Nucleic Acids Res; 2002 Dec; 30(23):5160-7. PubMed ID: 12466540
[TBL] [Abstract][Full Text] [Related]
78. Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing.
Peacey E; Rodriguez L; Liu Y; Wolfe MS
Nucleic Acids Res; 2012 Oct; 40(19):9836-49. PubMed ID: 22844088
[TBL] [Abstract][Full Text] [Related]
79. Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice.
Kakiuchi-Kiyota S; Koza-Taylor PH; Mantena SR; Nelms LF; Enayetallah AE; Hollingshead BD; Burdick AD; Reed LA; Warneke JA; Whiteley LO; Ryan AM; Mathialagan N
Toxicol Sci; 2014 Mar; 138(1):234-48. PubMed ID: 24336348
[TBL] [Abstract][Full Text] [Related]
80. Cathepsin B expression and down-regulation by gene silencing and antisense DNA in human chondrocytes.
Zwicky R; Müntener K; Goldring MB; Baici A
Biochem J; 2002 Oct; 367(Pt 1):209-17. PubMed ID: 12086583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
